Neuren Open-Label Study of Oral NNZ-2591
The purpose of the study is to look at the safety, tolerability, and efficacy of NNZ-2591 in the treatment of children…
Neuren Phase 2 trial Investor Presentation
Neuren has released a statement that the drug was found to be generally safe at the dose tested, having no serious adverse effects.
Press Release – Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome
Neuren has released a statement that the drug was found to be generally safe at the dose tested, having no serious adverse effects.